FAST NEWS: Ascletis Pharma’s Monkeypox Drug Gets IND Approval
The latest: Ascletis Pharma Inc. (1672.HK) announced on Thursday that the China National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for its oral viral polymerase…
Recent Articles
RECENT ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
